人体肿瘤髓系来源抑制性细胞的研究进展  

Research progress of myeloid-derived suppressor cells in patients with tumor

作　　者：蒋京伟 梁晓华 

机构地区：[1]复旦大学附属华山医院肿瘤科复旦大学上海医学院肿瘤学系,上海200040

出　　处：《国际肿瘤学杂志》2013年第8期575-578,共4页Journal of International Oncology

基　　金：国家自然科学基金（81101551）

摘　　要：髓系来源抑制性细胞（MDSC）是一群来源于髓系的异质性未分化成熟的细胞；在感染、创伤、败血症，尤其是肿瘤等病理状态下，MDSC在血液、淋巴器官、脾脏及肿瘤等组织中大量聚集；MDSC可以通过多种机制抑制肿瘤免疫，MDSC在患者外周血的数量与肿瘤的分期、负荷、远处转移及患者的预后密切相关。然而关于MDSC的研究结果大部分来自小鼠实验，由于肿瘤患者MDSC的表型比较复杂，其研究进展相对缓慢。Myeloid-derived suppressor cells （MDSCs） are a group of heterogeneous and immature mye- loid-derived cells, which accumulate largely in blood, lymphoid organs, spleen and tumor tissue and so on under the different pathogenic conditions such as infection, trauma, hematosepsis, especially tumor and so on. MDSCs can suppress tumor immune through many mechanisms. The number of MDSCs in periphery blood of patients is closely related with tumor stage, tumor burden, remote metastasis and prognosis. The major results are from laboratory mice. Because of the complexity of MDSCs in patients with tumor, there are many difficul- ties and debate on the research of them, and the researches of human MDSCs progress slowly.

关 键 词：髓系细胞 免疫耐受 肿瘤逃逸 

分 类 号：R730.3[医药卫生—肿瘤]